Tocilizumab
What's New
Last Posted: Apr 22, 2021
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
REMAP CAP investigators, NEJM, April 21, 2021 - Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Hässler Signe, et al. PLoS medicine 2020 0 (10) e1003348 - Pharmacogenomics of COVID-19 therapies.
Takahashi Takuto et al. NPJ genomic medicine 2020 Aug 5(1) 35 - Prognostic and predictive biomarkers in patients with COVID-19 treated with tocilizumab in a randomised controlled trial
J Tom, MEDRXIV, December 26, 20320 - FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
Jiménez Morales Alberto, et al. Journal of clinical pharmacology 2019 4 (4) 517-531 - Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
Maldonado-Montoro Mar, et al. Pharmacological research 2016 0 264-271 - Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.
Naito Takafumi, et al. Clinical biochemistry 2019 5 - A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.
Luxembourger Cécile, et al. The pharmacogenomics journal 2019 1 - Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga Tomohiro et al. Trials 2018 Dec 19(1) 715 - IL6R haplotype rs4845625*T/rs4537545*C is a risk factor for simultaneously high CRP, LDL and ApoB levels.
Arguinano A A, et al. Genes and immunity 2017 8
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Apr 26, 2021
- Content source: